
Enable job alerts via email!
Generate a tailored resume in minutes
Land an interview and earn more. Learn more
A global medical products company is seeking a Medical Affairs Specialist in Oxford. The role involves supporting clinical evidence generation for medical devices, developing Market Access Plans, and collaborating with cross-functional teams. Ideal candidates will have at least 10 years in medical or scientific affairs, strong problem-solving abilities, and relevant advanced degrees in biopharmaceutical or biomedical sciences. The position offers the chance to make impactful contributions within a leading healthcare organization.
The Medical Affairs Specialist for CNAP is a key point of contact for the Business Area helping the Director of Medical Affairs CNAP to drive the generation of the clinical evidence needs of Convatecs Next Generation Adaptive Platforms. Specifically this role will contribute to ConvaNiox. The role is responsible for being part of the medical affairs team by contributing to the development and delivery of the ConvaNiox clinical roadmap. This includes developing any Market Access and Evidence Plans (MAEP) conducting post‑market surveillance contributing to the development of any other clinical studies i.e. RCTs Observational. The role will work with the Director of Medical Affairs CNAP to identify the evidence needs to deliver the commercial strategy and make recommendations on how to address them in an effective and efficient manner.
Pioneering trusted medical solutions to improve the lives we touch : Convatec is a global medical products and technologies company focused on solutions for the management of chronic conditions with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10 000 colleagues we provide our products and services in around 90 countries united by a promise to be forever caring. Our solutions provide a range of benefits from infection prevention and protection of at‑risk skin to improved patient outcomes and reduced care costs. Convatecs revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE : CTEC). To learn more please visit